3rd Quarter - Report — AMERICAN DIABETES ASSOCIATION for AMERICAN DIABETES ASSOCIATION (2026)

Firm

AMERICAN DIABETES ASSOCIATION

Client

AMERICAN DIABETES ASSOCIATION

Income

—

Expenses

$100,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

SAFE Drugs Act (H.R.6509/ S.3794); Diabetes Act (S. 4037) and competitive bidding program; INSULIN Act (H.R. 10227/ S. 4189); Diabetes foot health (H.R. 7905/H.R. 1616/S. 4070/ S. 1805); Childhood Diabetes Reduction Act (S. 5026); Special Diabetes Program Reauthorization (NIH and IHS); Appropriations for National Institutes of Health and Centers for Disease Control and Prevention; Issues related to insurance reform.

Lobbyist	Covered position, as disclosed
GWEN RATHBUN New	—
JENNIFER SHERMAN New	—

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE

Bills named: S. 3794 (119th), H.R. 1616 (119th), S. 4189 (119th), S. 4070 (119th), H.R. 10227 (119th), H.R. 6509 (119th), H.R. 7905 (119th), S. 1805 (119th), S. 5026 (119th), S. 4037 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.